Skip to content
Company Analysis

Eli Lilly and Company LLY

A comprehensive view of key metrics, scores, and financial health for Eli Lilly and Company

Overview of Eli Lilly and Company

LLY NYQ
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Mega Cap
Eli Lilly and Company (LLY), is a Mega Cap company, in the Drug Manufacturers - General industry, last closed at $1133.00, about 82.2% overvalued vs fair value, +38.3% 1Y return, placing in the top 10% of its sector.
Metrics P/E 998.8× Rev Growth -2.9% ROE 4.9% Gross Margin 18.0% Div Yield 0.53%
USD 1133.00
-2.41%
(Delayed)
• Vol 90d: 41.8%
52-Week Range
Market Cap
$1.07T
Enterprise Value
$1.07T
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Fair
Efficiency
Weak
Valuation
Fair
Growth
Fair
Profitability
Weak
Health
Fair
Efficiency
Weak
Valuation
Fair
Completeness: 82%
Confidence: 56%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.lilly.com
HQ Indianapolis, IN
Employees 50,000
Fiscal year Dec 31

Next Events

Earnings Aug 5 Call: Aug 5

Fair Value Snapshot

Bear Base Bull
$183
$202
$222
Current: $1133.00 -82% vs base

Engine Room Money Flow™

Mega Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$94.8B
-2.9%%
Gross Profit
$17.1B
-2%%
R&D Expense
$6.4B
41.2%%
Operating Income (EBIT)
$5.6B
-39.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
262.6%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$9.5B
152.6% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
5
Active Leaks
2/5
Improving
1
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Eli Lilly and Company's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
48
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
39
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing LLY's balance between Growth (22.1%), Profitability (35.7%), and Safety (42.2%). Growth 22% Safety 42% Profitability 36%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

34th percentile vs peers
34
Key Signals
Revenue CAGR 3Y 5.2% 51p TSR 39.9% 73p Rev Growth YoY -2.9% 22p EPS Growth YoY -51.5% 22p EPS CAGR 3Y -33.3% 17p
Strengths
  • Interest Coverage Ratio in top 20% of peers (16.62, 89th percentile)
  • Cash Flow to Debt Ratio in top 20% of peers (5.46, 94th percentile)
Risks
  • Growth below peer median (percentile: 34)

Profitability

55th percentile vs peers
55
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

65th percentile vs peers
65
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Eli Lilly and Company.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$201.72
- - -
-82.2% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000